Amir M Sherif

List of Publications by Year
in descending order

80 papers	3,796 citations	257450 24 h-index	128289 60 g-index
83 all docs	83 docs citations	83 times ranked	4298 citing authors

#	Article	IF	Citations
1	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. European Urology, 2014, 65, 778-792.	1.9	868
2	Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. European Urology, 2011, 59, 1009-1018.	1.9	570
3	Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer. European Urology, 2012, 61, 1229-1238.	1.9	230
4	Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic Studies. European Urology, 2004, 45, 297-303.	1.9	220
5	Neoadjuvant Cisplatin-Methotrexate Chemotherapy for Invasive Bladder Cancer - Nordic Cystectomy Trial 2. Scandinavian Journal of Urology and Nephrology, 2002, 36, 419-425.	1.4	164
6	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. European Urology, 2014, 66, 1065-1077.	1.9	164
7	FOXP3 and survival in urinary bladder cancer. BJU International, 2011, 108, 1672-1678.	2.5	139
8	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
9	LYMPHATIC MAPPING AND DETECTION OF SENTINEL NODES IN PATIENTS WITH BLADDER CANCER. Journal of Urology, 2001, 166, 812-815.	0.4	97
10	EAUâ€"ESMO consensus statements on the management of advanced and variant bladder cancerâ€"an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	1.2	96
11	Hybrid SPECT-CT: An Additional Technique for Sentinel Node Detection of Patients with Invasive Bladder Cancer. European Urology, 2006, 50, 83-91.	1.9	79
12	Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival. BJU International, 2016, 117, 287-292.	2.5	76
13	The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clinical and Experimental Immunology, 2013, 172, 490-499.	2.6	57
14	Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies. Journal of Immunology, 2013, 190, 5847-5855.	0.8	53
15	Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clinical and Experimental Immunology, 2018, 194, 39-53.	2.6	48
16	Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness. Cancer Immunology Research, 2018, 6, 528-538.	3.4	45
17	Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). BMJ Open, 2017, 7, e016606.	1.9	44
18	Detection of Immune Responses Against Urinary Bladder Cancer in Sentinel Lymph Nodes. European Urology, 2006, 49, 59-70.	1.9	39

#	Article	IF	Citations
19	Urinary Exosomes from Bladder Cancer Patients Show a Residual Cancer Phenotype despite Complete Pathological Downstaging. Scientific Reports, 2020, 10, 5960.	3.3	35
20	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Science Translational Medicine, 2021, 13, .	12.4	35
21	Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumourâ€draining lymph nodes. BJU International, 2012, 109, 1134-1139.	2.5	29
22	Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer. European Urology, 2018, 74, 688-692.	1.9	28
23	Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept. European Urology, 2010, 58, 105-111.	1.9	27
24	Early Metastatic Progression of Bladder Carcinoma: Molecular Profile of Primary Tumor and Sentinel Lymph Node. Journal of Urology, 2002, 168, 2240-2244.	0.4	26
25	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. European Urology, 2017, 72, 509-518.	1.9	26
26	Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer. Tumor Biology, 2008, 29, 311-322.	1.8	25
27	Tumourâ€associated B cells in urothelial urinary bladder cancer. Scandinavian Journal of Immunology, 2020, 91, e12830.	2.7	25
28	Treatment of muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2007, 7, 1279-1283.	2.4	24
29	Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. Clinical Immunology, 2017, 176, 63-70.	3.2	24
30	Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFÎ²2 mediated pathway. PLoS ONE, 2018, 13, e0200079.	2.5	24
31	Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. Clinical Epigenetics, 2018, 10, 102.	4.1	24
32	Detection of micrometastases by flow cytometry in sentinel lymph nodes from patients with renal tumours. British Journal of Cancer, 2016, 115, 957-966.	6.4	23
33	Endovascular Approach to Treating Secondary Arterioureteral Fistula. Scandinavian Journal of Urology and Nephrology, 2002, 36, 80-82.	1.4	21
34	Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. Journal of Urology, 2001, 166, 812-5.	0.4	21
35	Evaluation of the diagnostic accuracy of UBC^{Â®} Rapid in bladder cancer: a Swedish multicentre study. Scandinavian Journal of Urology, 2017, 51, 293-300.	1.0	17
36	No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. World Journal of Urology, 2020, 38, 381-388.	2.2	17

#	Article	IF	Citations
37	Incidence, survival and mortality trends of bladder cancer in Sweden 1997â€“2016. Scandinavian Journal of Urology, 2019, 53, 193-199.	1.0	15
38	Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. World Journal of Urology, 2017, 35, 921-927.	2.2	14
39	Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. Scandinavian Journal of Urology, 2015, 49, 453-462.	1.0	13
40	Periodâ€specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care: a nationwide populationâ€based study. BJU International, 2019, 124, 449-456.	2.5	10
41	Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour. Cancers, 2021, 13, 3242.	3.7	10
42	Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1215-1224.	1.6	9
43	A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy. SpringerPlus, 2016, 5, 1167.	1.2	9
44	Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. Scandinavian Journal of Urology, 2018, 52, 186-193.	1.0	9
45	The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation. International Urology and Nephrology, 2020, 52, 661-669.	1.4	9
46	Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scandinavian Journal of Urology, 2019, 53, 206-212.	1.0	8
47	Cumulative incidence of ureteroenteric strictures after radical cystectomy in a population-based Swedish cohort. Scandinavian Journal of Urology, 2021, 55, 361-365.	1.0	8
48	Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. Scandinavian Journal of Urology, 2022, 56, 137-146.	1.0	8
49	Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node. Journal of Urology, 2002, 168, 2240-4.	0.4	8
50	Management and outcome of muscle-invasive bladder cancer with clinical lymph node metastases. A nationwide population-based study in the bladder cancer data base Sweden (BladderBaSe). Scandinavian Journal of Urology, 2019, 53, 332-338.	1.0	7
51	Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. Bladder Cancer, 2018, 4, 1-7.	0.4	6
52	A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer. Scandinavian Journal of Urology, 2021, 55, 108-115.	1.0	6
53	Nomograms including the UBC^{Â®} Rapid test to detect primary bladder cancer based on a multicentre dataset. BJU International, 2022, 130, 754-763.	2.5	6
54	ILâ€16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity. Scandinavian Journal of Immunology, 2020, 92, e12926.	2.7	5

#	Article	IF	Citations
55	Control computerized tomography in neoadjuvant chemotherapy for muscle invasive urinary bladder cancer has no value for treatment decisions and low correlation with nodal status. Scandinavian Journal of Urology, 2021, 55, 455-460.	1.0	5
56	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. Scandinavian Journal of Urology, 2022, 56, 27-33.	1.0	5
57	Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience. Scandinavian Journal of Urology, 2022, 56, 227-232.	1.0	5
58	The many flavors of tumor-associated B cells. OncoImmunology, 2013, 2, e25237.	4.6	4
59	The long perspective in emergence of neoadjuvant chemotherapy for bladder cancer in Ontario, Canadaâ€"space for improvement with regular and organized multidisciplinary team meetings. Translational Andrology and Urology, 2018, 7, 508-510.	1.4	4
60	Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. World Journal of Urology, 2020, 38, 2207-2213.	2.2	4
61	Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study. Scandinavian Journal of Urology, 2022, 56, 14-18.	1.0	4
62	Treatment and prognosis of patients with urinary bladder cancer with other primary cancers: a nationwide populationâ€based study in the Bladder Cancer Data Base Sweden (BladderBaSe). BJU International, 2020, 126, 625-632.	2.5	3
63	Computerized tomography before the final treatment cycle of neoadjuvant chemotherapy or induction chemotherapy in muscle- invasive urinary bladder cancer, cannot predict pathoanatomical outcomes and does not reflect prognosisâ€"results of a single centre retrospective prognostic study. Translational Andrology and Urology, 2020, 9, 1062-1072.	1.4	3
64	Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. Scandinavian Journal of Urology, 2020, 54, 46-51.	1.0	3
65	RE: EXTENDED RADICAL LYMPHADENECTOMY IN PATIENTS WITH UROTHELIAL BLADDER CANCER: RESULTS OF A PROSPECTIVE MULTICENTER STUDY. Journal of Urology, 2004, 172, 386-386.	0.4	2
66	Editorial Comment on: FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer. European Urology, 2010, 57, 647.	1.9	2
67	Detection of micro-metastases by flow cytometry in lymph nodes from patients with penile cancer. BMC Urology, 2018, 18, 86.	1.4	2
68	Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study. PLoS ONE, 2021, 16, e0246703.	2.5	2
69	Survival after radical cystectomy during holiday periods. Scandinavian Journal of Urology, 2021, 55, 276-280.	1.0	2
70	A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer. Scandinavian Journal of Urology, 2022, 56, 20-26.	1.0	2
71	Response to Comment on â€œMultiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignanciesâ€• Journal of Immunology, 2013, 191, 4471.2-4472.	0.8	1
72	The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, S337-S340.	1.4	1

#	Article	IF	Citations
73	Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study. Bladder Cancer, 2021, 7, 161-171.	0.4	1
74	Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer. Investigative and Clinical Urology, 2021, 62, 39.	2.0	1
75	Sustainable long-term results on postoperative sexual activity after radical prostatectomy when a clinical sexologist is included in the sexual rehabilitation process. A retrospective study on 7 years postoperative outcome. Central European Journal of Urology, 2020, 73, 551-557.	0.3	1
76	Thromboembolic events during neoadjuvant chemotherapy in muscle invasive bladder cancer â€“ any correlation to the central venous access? A clinical practice article. F1000Research, 0, 11, 40.	1.6	1
77	B cells in tumor draining lymph nodes act as efficient antigen presenting cells in cancer patients. , 2015, 3, .		0
78	Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe). Scandinavian Journal of Urology, 2019, 53, 200-205.	1.0	0
79	Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2007, 33, 840-841.	1.5	0
80	Do not throw out the baby with the bath water. Scandinavian Journal of Urology, 2022, 56, 235-236.	1.0	0